Researchers from Boston University and Howard University Cancer Center found no association between hair relaxer use and increased breast cancer risk among 48,167 African-American women. The study's lead investigator notes that hair relaxers are not a cause of breast cancer, contradicting previous speculation.
Researchers found no association between lycopene and prostate cancer prevention, contrary to previous studies. A diet rich in beta-carotene, another antioxidant, was linked to an increased risk of aggressive prostate cancer.
Recent studies have found that PTEN and HER2 genes regulate self-renewal and invasion of human mammary stem cells, making them potential targets for breast cancer treatment. Additionally, radiation therapy may contribute to leukemia risk by recruiting hematopoietic stem cells into the irradiated bone marrow.
The AACR-FDA-NCI Cancer Biomarkers Collaborative aims to integrate predictive biomarkers into clinical trials, addressing the translation of cancer knowledge into medical practice. The collaborative will develop guidelines for biomarker validation, informing policies as part of the FDA's Critical Path Initiative.
Researchers at the University of Massachusetts have found that nanoparticles can cause DNA damage in breast cancer cells, increasing the risk of cancer. The study suggests that smaller particles are more likely to enter cells and cause toxicity, highlighting the need for further research on nanoparticle safety.
New cancer vaccine studies are making progress in developing vaccines that can attack cancerous cells by stimulating the immune system. Researchers have found that a human papillomavirus vaccine continues to protect against HPV types 16 and 18, as well as other related viruses, with significant cross-protection.
Researchers have identified gene expression signatures that can predict how individuals will respond to certain breast cancer drugs. These biomarkers could aid in tailoring treatments for women and identifying similar biomarkers for other types of cancer. A 'systems' approach suggests prioritizing experimental medicines for specific ca...
Researchers are developing gene therapies that can target and kill cancer cells, while also exploring the use of viruses and other natural systems to design new cancer treatments. Studies have shown promising results in animal models, including a novel gene therapy approach that eradicates aggressive prostate cancer.
A phase III trial of darbepoetin alfa found that the drug did not reduce blood transfusion risk in non-chemotherapy patients, but increased overall patient mortality. Patients with certain types of cancer saw better survival outcomes when treated with the drug.
Two studies suggest that reducing inflammation with aspirin or inhaler medications may help control cancer. One study found regular aspirin users had a 16% reduced risk of developing cancer, while another discovered a link between asthma and increased lung metastasis risk.
The American Association for Cancer Research (AACR) and Susan G. Komen for the Cure have launched a partnership to address cancer disparities and promote prevention. The $2M pledge will support educational outreach, public forums, and research initiatives.
Researchers found that early age at first birth protects against ERPR-positive breast cancer, but not receptor-negative. Breastfeeding was protective for both subtypes, regardless of when a woman gave birth. Women who delay childbearing may benefit from breastfeeding to reduce their risk.
A phase III trial of 1,298 patients found that a combination of cetuximab and irinotecan increased progression-free survival over irinotecan alone. The treatment also showed a higher tumor response rate.
Researchers found that cetuximab improved overall survival by 23% and reduced disease progression risk by 32%. The drug targets the EGFR receptor on cancer cells, preventing cell growth and triggering an immune response.
A study found that breast cancer risk is associated with epigenetic changes related to racial group, smoking status, and infant and childhood size. Researchers analyzed DNA methylation patterns in a cohort of women born between 1959 and 1966, finding correlations between these factors and increased breast cancer susceptibility.
Researchers have developed tests that diagnose, predict or monitor cancer risks without invasive tissue sampling, benefiting underserved populations. DNA methylation mapping from exhaled breath can identify early-stage lung cancer, while an oral rinse test detects head and neck squamous cell carcinoma
Research suggests that genetics, socioeconomic status, and neighborhood environment play a role in cancer incidence and mortality disparities among African-Americans, Hispanics, and Caucasians. A survey found that late-stage cancer diagnosis is more common among older, low-income individuals living in unsafe neighborhoods.
Researchers have discovered a biological mechanism whereby two compounds in broccoli and soy reduce the invasive and metastatic potential of breast and ovarian cancer cells. Studies also suggest that a diet high in flavonols may help reduce pancreatic cancer risk, especially in smokers.
The American Association for Cancer Research (AACR) has awarded its inaugural Team Science Award to a multidisciplinary team of researchers from the University of Michigan and Harvard Medical School/Brigham and Women's Hospital. The award recognizes their groundbreaking discovery of gene fusions in prostate cancer, which has significan...
The American Association for Cancer Research will present the AACR Distinguished Service Award and the AACR Public Service Award to Dr. Andrew C. von Eschenbach, Dr. Harold P. Freeman, and Dr. LaSalle D. Leffall, Jr., recognizing their outstanding contributions to leadership, education, and advocacy in cancer research. The awards will ...
The American Association for Cancer Research (AACR) has awarded $1.275 million in grants to 18 promising cancer scientists. The career development awards and research fellowships support early-career scientists at various stages of their careers.
Ambassador Nancy Brinker, founder of Susan G. Komen for the Cure, will receive a Centennial Medal for her sustained effort in fighting breast cancer. Lance Armstrong, cancer survivor and seven-time Tour De France winner, will be honored for his advocacy work.
Aflac has expanded its support for the American Association for Cancer Research (AACR), providing funding for four young investigators in pediatric cancer research through the AACR-Aflac Career Development Award. The awards also enhance education for early-career scientists attending the AACR Annual Meeting.
Margaret Foti receives AACR Award for her leadership of the organization and her dedication to cancer research. She has successfully launched four high-quality journals and created the AACR Special Conference series, bringing innovation to scientific presentation and exchange.
The American Association for Cancer Research (AACR) established a new lecture in honor of Princess Takamatsu, recognizing Webster K. Cavenee's groundbreaking research on genetic mechanisms of cancer predisposition. Cavenee will present his inaugural lecture on April 17, highlighting the importance of collaborations in cancer research.
Danishefsky's work has provided major fundamental advances in organic synthesis and impacted the treatment of cancer, with novel compounds currently in clinical trials. He is recognized as one of the world's leading chemists and a celebrated researcher, with numerous awards and honors including the Wolf Prize in Chemistry.
The American Association for Cancer Research (AACR) is honoring world-class cancer researchers who have made significant contributions to the fight against cancer. The winners of the 2007 AACR research achievement awards include Dr. Janet S. Butel, Dr. Harold P. Freeman, and Dr. Alexander Varshavsky.
Donald Metcalf is recognized for his groundbreaking research on blood cell formation and colony-stimulating factors, which revolutionized cancer treatment. His work led to the development of therapies accelerating hematopoietic regeneration in patients, reducing infection risk and shortening hospital stays.
The AACR-Bardos Awards program offers financial support to third-year undergraduate students majoring in science, allowing them to attend the Annual Meeting 2007 and present their research. Winners also participate in the Undergraduate Student Caucus and Poster Competition.
The American Association for Cancer Research (AACR) has awarded scholarships to 61 underrepresented scientists to participate in the AACR Annual Meeting. The awardees include early-career researchers from historically black colleges and universities, Hispanic-serving institutions, and tribal colleges and universities.
Bissell's work revolutionized understanding of cancer biology, revealing that the interaction between cells and extracellular matrix influences cell proliferation, survival, and differentiation. Her research has brought closer to a complete understanding of how living cells function in three-dimensional tissue.
The Kirk A. Landon-AACR Prize for Basic Cancer Research recognizes Dr. Richard Kolodner for his work on DNA mismatch repair and its connection to human cancer. The Dorothy P. Landon-AACR Prize for Translational Cancer Research honors Douglas Lowy and John Schiller for their development of the human papillomavirus vaccine.
Scientists have discovered that an attenuated form of poliovirus can effectively destroy neuroblastoma tumors in mice without harming them. The study's findings suggest that this approach could represent a new, safe means of treating childhood cancer and potentially other cancers in adults.
Scientists have found a way to activate EBV inside tumors, allowing them to identify patients whose infection can be manipulated to destroy their tumors. The technique uses two agents already on the market to light up tumor viruses, offering a novel approach to treating cancers associated with Epstein-Barr.
Researchers found that a combination of green tea polyphenol EGCG and COX-2 inhibitor celecoxib can slow the growth of human prostate cancer. The study demonstrated a synergistic effect, where both agents triggered cellular pathways that were more powerful when combined.
Researchers used gene chips to profile tumors before treatment and found markers that identified breast cancer subtypes resistant to Herceptin. They discovered that IGF-1R expression was associated with a lower response rate, and that resistant tumors continued to over-express the HER2 growth factor protein.
Researchers found that telomere length shortens with every successive generation in families with Li-Fraumeni syndrome, resulting in more severe cancers at an earlier age. This discovery could represent the first biological marker for clinical monitoring in these families.
Researchers at Memorial Sloan-Kettering Cancer Center found that only nine of 70 Phase II studies clearly defined measures to judge experimental drug effectiveness. This limits the accuracy of testing new treatments for cancer patients.
Researchers used toll-like receptor agonists to stimulate an immune response against breast cancer tumors, preventing spontaneous growth and slowing tumor development. The vaccine was most effective when given prior to tumor appearance, extending survival but not curing the disease.
Researchers identified human pancreatic cancer stem cells, which can produce tumors in half of mice tested. These stem cells are highly tumorigenic and resistant to traditional therapy, making them a promising target for new treatments.
Researchers developed a simple and non-invasive gene probe to diagnose early stage lung cancer in current and former smokers. The test identified 76% of stage I lung cancer patients whose tumors also showed the same genetic loss, outperforming existing sputum cytology tests.
Researchers have found a selective marker in nestin that could lead to earlier detection and better treatment of basal epithelial breast tumors, a highly aggressive form of breast cancer. High levels of nestin were detected in 14 out of 16 tumor samples examined.
Scientists have discovered two protein biomarkers associated with breast cancer spread, which could help predict patient outcomes and guide treatment decisions. The study found that overexpression of one protein and underexpression of another were highly accurate in identifying patients at risk of metastasis.
Two microRNAs, miR-29 and miR-181, have been found to control the expression of the TCL1 oncogene responsible for aggressive forms of B-cell chronic lymphocytic leukemia. High levels of these miRNAs suppress TCL1 expression, while low levels correlate with more aggressive cancer.
A study found that close to half of smokers who underwent early-stage lung cancer surgery resumed smoking within 12 months, with 60% resuming in the first two months. Patients' self-efficacy and perceived pleasure from smoking drove their relapse rates.
A study of over 36,000 women found that regular exercise can lower a smoker's lung cancer risk by 28%, but quitting smoking remains the most effective way to reduce risk. The absolute risk of developing lung cancer is still higher for current and former smokers, regardless of activity level.
Researchers developed a vaccine that stimulates colorectal cancer patients' immune systems to fight cancerous cells, with 70% of patients producing TNF-alpha and GM-CSF in response. The vaccine works by generating infection-fighting white blood cells called T cells, which destroy cancer cells.
Studies found that eating fish regularly reduces the risk of colorectal cancer by 40%, while childhood soy intake is associated with a 58% decrease in breast cancer risk. Vitamin use and smoking also show protective effects, providing valuable insights into diet's role in cancer prevention.
Exercise has been found to reduce colon cancer risk in men who engage in moderate to vigorous exercise for a year. Aspirin consumption may also negate the harmful effects of eating flame-broiled meat, particularly among breast cancer survivors. Childbearing may also be linked to an increased lung cancer risk.
Scientists discover plant-derived triterpenoids and rexinoid LG100268 significantly reduce tumor growth in mice, offering potential future chemoprevention methods. The compounds inhibit inflammation and induce apoptosis in human lung cancer cells, presenting a promising avenue for preventing lung cancer.